MHY1485: mTOR Activator and Autophagy Inhibitor for Advan...

2026-02-17

MHY1485: mTOR Activator and Autophagy Inhibitor for Advanced Research

Principle Overview: MHY1485 as a Dual-Action Tool in mTOR and Autophagy Research

MHY1485 (SKU: B5853) is a potent small-molecule activator of the mechanistic target of rapamycin (mTOR), a central kinase orchestrating cellular metabolism, growth, and survival. Unlike traditional mTOR modulators, MHY1485 exhibits a unique dual mechanism: it stimulates the mTOR signaling pathway while simultaneously inhibiting autophagy by suppressing the fusion between autophagosomes and lysosomes. This results in the accumulation of LC3II and enlarged autophagosomes, providing researchers with a powerful lever to dissect the interplay between mTOR activity and autophagic flux. Sourced reliably from APExBIO, MHY1485 has become essential in studies spanning cancer biology, neurodegenerative disease models, cell proliferation and survival, and ovarian follicle development research.

mTOR activator and autophagy inhibitor: Enables precise pathway dissection and functional interrogation.
Induces autophagy inhibition by suppression of autophagosome-lysosome fusion: Blocks the late phase of autophagic flux, a feature critical for mechanistic studies.
Solubility profile: Insoluble in water and ethanol, but highly soluble in DMSO (≥19.35 mg/mL), supporting concentrated stock preparations for robust experimental workflows.

For a comprehensive background on MHY1485's mechanism and research versatility, see this article, which details its strategic role in dissecting cell survival pathways and disease modeling.

Step-by-Step Workflow: Integrating MHY1485 into Experimental Protocols

1. Preparation of MHY1485 Stock Solutions

Dissolve MHY1485 in DMSO to achieve a 10 mM stock solution (≥19.35 mg/mL).
Vortex and, if needed, sonicate to ensure full dissolution, especially at higher concentrations.
Aliquot and store at -20°C. Minimize freeze-thaw cycles—use freshly thawed aliquots promptly to maintain compound integrity.

2. Cell-Based Assay Implementation

For autophagy assays, treat cells (e.g., Ac2F rat hepatocytes, cancer cell lines, or primary neurons) with MHY1485 at concentrations ranging from 1–10 μM, depending on cell sensitivity and experimental goals.
Include appropriate controls: vehicle (DMSO), mTOR inhibitor (e.g., rapamycin), and autophagy agonist (e.g., MG-132) for comparative readouts.
Monitor autophagic markers (LC3II, p62/SQSTM1) and mTOR pathway activation (p-mTOR, p-p70S6K) via immunoblotting or fluorescence microscopy.

3. Ovarian Follicle Development and Grafting Models

Apply MHY1485 in juvenile mouse ovary cultures at optimal doses (1–5 μM) to promote follicle growth and graft weight, as previously demonstrated.
Track folliculogenesis using histology, follicle counts, and molecular markers of proliferation (Ki-67, PCNA).

4. Advanced Disease Modeling

In cancer biology research, leverage MHY1485 to manipulate mTOR-driven proliferation and study autophagy's role in tumorigenesis, as exemplified in uveal melanoma (UM) models (see reference study).
For neurodegenerative disease models, use MHY1485 to interrogate the interplay between mTOR signaling and autophagic impairment, mimicking disease-relevant conditions.

For further experimental benchmarks and best practices, this resource provides an in-depth look at workflow integration and protocol customization for MHY1485.

Advanced Applications: Comparative Advantages of MHY1485

Precision in mTOR signaling pathway interrogation: Unlike rapamycin, which is an inhibitor, MHY1485 directly activates mTOR, enabling upregulation studies and pathway mapping.
Autophagy inhibition by suppression of autophagosome-lysosome fusion: MHY1485 blocks autophagic flux at a late stage, permitting accumulation of autophagosomes—a critical readout for autophagy assays.
Ovarian follicle development research: MHY1485 promotes follicle expansion and graft viability, offering a robust model for reproductive biology and regenerative medicine.
Cell proliferation and survival studies: By modulating both mTOR and autophagy, MHY1485 supports nuanced analyses of cell fate under stress and during tumorigenesis.
Relevance in cancer and neurodegenerative disease research: As demonstrated in the referenced study (Liu et al., 2023), MHY1485 was used to counteract autophagy induction by LINC01278, illustrating its value in pathway validation and mechanistic dissection in UM and potentially other cancers.

To see how MHY1485 compares and complements other tools, this article expands on its role in translational research, emphasizing strategic deployment in cancer and neurodegeneration studies.

Troubleshooting and Optimization Tips for MHY1485 Workflows

Solubility challenges: Always dissolve MHY1485 in DMSO; do not use water or ethanol. Warm and sonicate the solution if precipitation occurs.
Stock degradation: Avoid multiple freeze-thaw cycles. Prepare single-use aliquots and store at -20°C in the dark.
Cytotoxicity: Start with lower concentrations (1 μM) and titrate upward. Monitor cell viability with appropriate assays (MTT, trypan blue exclusion).
Assay controls: Pair MHY1485 experiments with both positive (rapamycin, known autophagy inducers/inhibitors) and negative controls for robust data interpretation.
Readout selection: Use a combination of immunoblotting, fluorescence imaging, and quantitative PCR for reliable assessment of autophagy and mTOR pathway activity.
Reproducibility: Document DMSO content in final working solutions (keep ≤0.1% v/v) to avoid solvent-associated artifacts.
Batch variation: When possible, purchase MHY1485 from a trusted supplier such as APExBIO to ensure lot-to-lot consistency and product quality.

Future Outlook: Expanding the Research Horizon with MHY1485

MHY1485 stands at the intersection of cellular signaling and disease modeling, enabling unprecedented granularity in dissecting the balance between growth and catabolic processes. As highlighted in the LINC01278-mTOR-autophagy axis study, strategic pathway targeting with MHY1485 can reveal new biomarkers and therapeutic targets for conditions such as uveal melanoma, with implications extending to other cancers and neurodegenerative disorders. Ongoing research is poised to exploit MHY1485's dual function for combination therapy screens, synthetic lethality paradigms, and regenerative medicine applications, especially in the context of ovarian follicle preservation and transplantation.

For researchers seeking to leverage MHY1485 in their experimental workflows, the compound’s established performance profile, supported by APExBIO, ensures both reliability and innovation at the bench. As demonstrated across recent literature and expert best-practice guides (see here for workflow enhancements and troubleshooting), MHY1485 is positioned to remain a cornerstone tool in the evolving landscape of mTOR and autophagy research.

References: